Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-label, Multicenter Study to Assess the Efficacy and Safety of BW-20805 in Adult Subjects With Hereditary Angioedema

NCT06846398 is registered in ClinicalTrials.gov with Shanghai Argo Biopharmaceutical Co., Ltd. as lead sponsor.

NCT NCT06846398
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06846398 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-label, Multicenter Study to Assess the Efficacy and Safety of BW-20805 in Adult Subjects With Hereditary Angioedema
Lead sponsor
Shanghai Argo Biopharmaceutical Co., Ltd.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 28, 2025
Completion date
March 30, 2028
Enrollment
25 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary angioedema (hae)